Literature DB >> 3316383

Kinetics and mechanisms of recombinant human interleukin 1 and tumor necrosis factor-alpha-induced changes in circulating numbers of neutrophils and lymphocytes.

T R Ulich1, J del Castillo, M Keys, G A Granger, R X Ni.   

Abstract

Human recombinant interleukins 1 alpha and 1 beta (rIL-1 alpha and -1 beta) both induced monophasic peripheral neutrophilia and lymphopenia in Lewis rats 1.5 hr after i.v. injection. The kinetics of rIL-1 alpha- and -1 beta-induced neutrophilia were similar to those induced by human monocyte-derived IL-1, IL-1 alpha, and IL-1 beta, and the peripheral neutrophilia was accompanied by a marked decrease in marrow neutrophils. Arachidonic acid metabolites are implicated as biochemical intermediates in the production of the neutrophilia but not lymphopenia, since indomethacin and dexamethasone both completely abrogated IL-1-induced neutrophilia but did not affect the IL-1-induced lymphopenia. Acetylsalicylic acid, a cyclooxygenase inhibitor, did not inhibit IL-1-induced neutrophilia, suggesting that products of the lipoxygenase rather than the cyclooxygenase pathway of arachidonate metabolism may contribute to the neutrophilia. Human recombinant tumor necrosis factor-alpha (rTNF) administered i.v. to Lewis rats induced peripheral neutropenia, two peaks of neutrophilia, and lymphopenia. A wide range of doses of rTNF resulted in an initial neutropenia at 0.5 hr after injection followed by a first peak of neutrophilia at 1.5 hr and a second peak of neutrophilia at 6 hr. The initial neutropenia and the first peak of neutrophilia were not inhibited by pretreatment of rats with dexamethasone, indomethacin, or aspirin. The second peak of neutrophilia was inhibited by both dexamethasone and indomethacin, but was not at all inhibited by aspirin, suggesting that the second peak of neutrophilia is mediated by the release of endogenous cytokines, especially by IL-1, since exogenous IL-1-induced neutrophilia is also completely inhibited by dexamethasone and indomethacin but not by aspirin. The TNF-induced peripheral neutrophilia is also accompanied by a significant depletion of bone marrow neutrophils, indicating that the source of increased circulating neutrophils is, at least in part, via recruitment of marrow neutrophils. Systemic blood pressure was not affected by IL-1 or rTNF at the dosages employed, showing that the changes in circulating leukocyte subsets were not attributable to hemodynamic changes nor to the hemodynamic change-related release of adrenal hormones. Adrenalectomy did not alter the IL-1- or rTNF-induced neutrophilia or lymphopenia, also demonstrating that neither monokine mediates its hematologic effects on peripheral blood leukocytes via the release of adrenal hormones.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3316383

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  64 in total

1.  Lymphocyte subsets and their proliferation in a model for a delayed-type hypersensitivity reaction in the skin.

Authors:  F J Fritz; R Pabst; R M Binns
Journal:  Immunology       Date:  1990-12       Impact factor: 7.397

2.  Prognostic significance of the ratio of absolute neutrophil to lymphocyte counts for breast cancer patients with ER/PR-positivity and HER2-negativity in neoadjuvant setting.

Authors:  Young Wha Koh; Hee Jin Lee; Jin-Hee Ahn; Jong Won Lee; Gyungyub Gong
Journal:  Tumour Biol       Date:  2014-07-02

3.  Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer.

Authors:  De-shen Wang; Hui-yan Luo; Miao-zhen Qiu; Zhi-qiang Wang; Dong-sheng Zhang; Feng-hua Wang; Yu-hong Li; Rui-hua Xu
Journal:  Med Oncol       Date:  2012-04-05       Impact factor: 3.064

4.  Comparison of peripheral blood leukocyte kinetics after live Escherichia coli, endotoxin, or interleukin-1 alpha administration. Studies using a novel interleukin-1 receptor antagonist.

Authors:  A S Hawes; E Fischer; M A Marano; K J Van Zee; C S Rock; S F Lowry; S E Calvano; L L Moldawer
Journal:  Ann Surg       Date:  1993-07       Impact factor: 12.969

5.  Role of tumor necrosis factor-alpha in lipopolysaccharide-induced pathologic alterations.

Authors:  D G Remick; R M Strieter; M K Eskandari; D T Nguyen; M A Genord; C L Raiford; S L Kunkel
Journal:  Am J Pathol       Date:  1990-01       Impact factor: 4.307

6.  Interaction of interleukin-6, tumour necrosis factor and interleukin-1 during Listeria infection.

Authors:  Z Liu; R J Simpson; C Cheers
Journal:  Immunology       Date:  1995-08       Impact factor: 7.397

7.  MDHM, a macrophage-stimulatory product of Mycoplasma fermentans, leads to in vitro interleukin-1 (IL-1), IL-6, tumor necrosis factor, and prostaglandin production and is pyrogenic in rabbits.

Authors:  P F Mühlradt; U Schade
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

8.  Endotoxin-induced cytokine gene expression in vivo. IV. Expression of interleukin-1 alpha/beta and interleukin-1 receptor antagonist mRNA during endotoxemia and during endotoxin-initiated local acute inflammation.

Authors:  T R Ulich; K Guo; S Yin; J del Castillo; E S Yi; R C Thompson; S P Eisenberg
Journal:  Am J Pathol       Date:  1992-07       Impact factor: 4.307

9.  A pre-operative elevated neutrophil: lymphocyte ratio does not predict survival from oesophageal cancer resection.

Authors:  Farhan Rashid; Naseem Waraich; Imran Bhatti; Shopan Saha; Raheela N Khan; Javed Ahmed; Paul C Leeder; Mike Larvin; Syed Y Iftikhar
Journal:  World J Surg Oncol       Date:  2010-01-06       Impact factor: 2.754

Review 10.  Dual functionality of interleukin-1 family cytokines: implications for anti-interleukin-1 therapy.

Authors:  N M Luheshi; N J Rothwell; D Brough
Journal:  Br J Pharmacol       Date:  2009-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.